Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Net Cash Flow (2019 - 2025)

Black Diamond Therapeutics' Net Cash Flow history spans 5 years, with the latest figure at -$9.9 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 175.91% year-over-year to -$9.9 million; the TTM value through Dec 2025 reached -$15.4 million, up 21.99%, while the annual FY2025 figure was -$15.4 million, 21.99% up from the prior year.
  • Net Cash Flow reached -$9.9 million in Q4 2025 per BDTX's latest filing, down from $874000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $62.0 million in Q1 2025 to a low of -$68.4 million in Q2 2025.
  • Average Net Cash Flow over 3 years is -$6.2 million, with a median of -$9.4 million recorded in 2024.
  • The largest YoY upside for Net Cash Flow was 301.24% in 2025 against a maximum downside of 1025.7% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at -$20.5 million in 2021, then surged by 163.44% to $13.0 million in 2024, then tumbled by 175.91% to -$9.9 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Net Cash Flow are -$9.9 million (Q4 2025), $874000.0 (Q3 2025), and -$68.4 million (Q2 2025).